NICOTINE POLACRILEX Drug Patent Profile

Which patents cover Nicotine Polacrilex, and what generic alternatives are available?

Nicotine Polacrilex is a drug marketed by Fertin Pharma, Ivax Sub Teva Pharms, L Perrigo Co, P And L, Perrigo R And D, Aurobindo Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Pld Acquisitions, and Ppi-dac. and is included in fifty NDAs.

The generic ingredient in NICOTINE POLACRILEX is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nicotine Polacrilex

A generic version of NICOTINE POLACRILEX was approved as nicotine polacrilex by P AND L on March 15^th, 1999.

Summary for NICOTINE POLACRILEX

US Patents:	0
Applicants:	10
NDAs:	50
Finished Product Suppliers / Packagers:	58
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	22
Drug Prices:	Drug price information for NICOTINE POLACRILEX
DailyMed Link:	NICOTINE POLACRILEX at DailyMed

See drug prices for NICOTINE POLACRILEX

See drug sales revenues for NICOTINE POLACRILEX

Recent Clinical Trials for NICOTINE POLACRILEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
22nd Century Group, Inc.	Phase 1
Vince & Associates Clinical Research, Inc.	Phase 1

See all NICOTINE POLACRILEX clinical trials

Pharmacology for NICOTINE POLACRILEX

Drug Class

Cholinergic Nicotinic Agonist

Anatomical Therapeutic Chemical (ATC) Classes for NICOTINE POLACRILEX

N07BA	Drugs used in nicotine dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for NICOTINE POLACRILEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NICORETTE	Troche/Lozenge (Mini)	nicotine polacrilex	2 mg and 4 mg	022360	1	2015-12-02

US Patents and Regulatory Information for NICOTINE POLACRILEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	NICOTINE POLACRILEX	nicotine polacrilex	TROCHE/LOZENGE;ORAL	212983-002	Feb 21, 2020		OTC	No	No
Aurobindo Pharma	NICOTINE POLACRILEX	nicotine polacrilex	TROCHE/LOZENGE;ORAL	213266-001	Aug 3, 2021		OTC	No	No
P And L	NICOTINE POLACRILEX	nicotine polacrilex	TROCHE/LOZENGE;ORAL	210712-001	Sep 6, 2019		OTC	No	No

Market Dynamics and Financial Trajectory for Nicotine Polacrilex

Last updated: February 13, 2026

---

What Is Nicotine Polacrilex?

Nicotine polacrilex is a form of nicotine used in over-the-counter smoking cessation products. It is a proprietary formulation combining nicotine with a polacrilin resin, designed for controlled release in the oral cavity. Common formulations include lozenges, gum, and patches, with lozenges being prominent.

Market Size and Growth

The global smoking cessation market was valued at approximately $12.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030. Nicotine polacrilex products account for roughly 30% of this market, with sales primarily driven by vaping restrictions and rising awareness around smoking harms.

Regulatory Landscape

1. FDA Regulation: In the U.S., nicotine polacrilex is classified as an over-the-counter (OTC) drug. Approval hinges on compliance with OTC monograph standards. The FDA monitors safety and efficacy data, with continued updates to labeling and marketing requirements.

2. European Market: The European Medicines Agency (EMA) governs nicotine replacement therapies. Most OTC products containing nicotine polacrilex are authorized through national agencies, and regulations are harmonized under the Tobacco Products Directive.

3. Emerging Legislation: Several countries are tightening marketing and sales restrictions for nicotine products, including bans on flavors in some regions, aiming to reduce youth access. This could influence product formulations and market size.

Market Drivers

• Rising health awareness and tobacco bans pressure smokers to switch to cessation aids.
• Increasing availability of OTC products, especially nicotine gum and lozenges.
• Patent expirations on branded products, encouraging generic competition.
• Technological improvements in formulation sustaining controlled release.

Market Constraints

• Stringent regulations and flavor bans reduce product diversification.
• Negative perceptions regarding nicotine, despite its role in cessation.
• Competition from alternative nicotine delivery systems, notably vaping devices, which are growing in prevalence.

Key Industry Players

Company	Market Share	Product Portfolio	Regulatory Status
Johnson & Johnson (Nicorette)	~15%	Nicorette gum, lozenges	Approved as OTC in multiple jurisdictions
GlaxoSmithKline (Nicorette)	~10%	Nicorette gum, lozenges	OTC approval worldwide
Perrigo Company	~8%	Nicotine lozenges, gum	OTC status, expanding to emerging markets

Financial Trajectory

The revenue from nicotine replacement therapies (NRTs) including nicotine polacrilex is projected to grow from $3.7 billion in 2022 to roughly $5 billion by 2030. This reflects a CAGR of approximately 4-5% in revenue terms, driven by increased volume sales rather than price increases.

• Historical Sales Trends: Post-2018, sales declined by 1-2% annually due to market saturation and the rise of alternative products.
• Forecasted Growth (2023-2030): Market expansion driven by increased adoption and product innovation, including slow adoption of higher-dose formulations and reformulations targeting new demographics.

R&D and Patent Landscape

Public and private investment in new nicotine delivery formulations continues. Several patents expire between 2023 and 2028, opening market entry for generics:

Patent Expiry	Primary Product	Impact
2023	Nicorette Lozenge	Increased generic competition
2025	Nicorette Gum	Entry of lower-cost alternatives

Competitive Strategy and Future Outlook

Company strategies emphasize innovation, such as:

• Developing sugar-free, flavor-restricted variants.
• Formulating extended-release lozenges.
• Targeting lower-income regions through cost reduction.

Attainment of newer markets, notably in Asia-Pacific, remains a priority, where smokeless tobacco alternatives are popular and regulatory barriers lag behind.

---

Key Takeaways

• Nicotine polacrilex is a cornerstone product in the OTC smoking cessation segment, expected to grow steadily despite increasing competition.
• Market expansion faces regulatory challenges, notably flavor bans and marketing restrictions.
• Patent expirations will accelerate generics' entry, pressuring prices and margins.
• Industry investment focuses on formulation enhancements and expanding into emerging markets.
• Overall, revenue growth will be moderate, driven by volume rather than pricing power.

---

FAQs

1. How does regulation affect the market for nicotine polacrilex?
   Regulations impact product approval, marketing, and formulation modifications, often leading to market consolidation and innovation in lower-risk designs.

2. What are the main competitors to nicotine polacrilex products?
   Vaping devices and other novel nicotine delivery systems are emerging competitors, capitalizing on consumer preferences for alternative delivery methods.

3. How significant are patent expirations for this market?
   Patents expiring between 2023 and 2028 open opportunities for generics, increasing price competition and affecting brand dominance.

4. What regions present the highest growth opportunities?
   Asia-Pacific and Latin America are rising markets due to increasing tobacco control measures and growing awareness of smoking-related health issues.

5. What innovations are influencing future sales?
   Innovations include controlled-release formulations, flavor restrictions, and lower-cost options tailored for emerging markets.

---

References

1. MarketWatch, "Global Smoking Cessation Market," 2022.
2. FDA, "OTC Nicotine Replacement Therapy Monograph," 2022.
3. European Medicines Agency, "Regulations on Nicotine Replacement Products," 2023.
4. IBISWorld, "Nicotine Replacement Therapy Industry Report," 2023.
5. GlobalData, "Market Trends in Nicotine Products," 2022.